LV13427B - Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours - Google Patents

Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours Download PDF

Info

Publication number
LV13427B
LV13427B LVP-05-152A LV050152A LV13427B LV 13427 B LV13427 B LV 13427B LV 050152 A LV050152 A LV 050152A LV 13427 B LV13427 B LV 13427B
Authority
LV
Latvia
Prior art keywords
antibody
light chain
instead
heavy
cdr
Prior art date
Application number
LVP-05-152A
Other languages
English (en)
Latvian (lv)
Inventor
Navarro Loudes Tatiana Roque
De Acosta Del Rio Cristi Mateo
Gonzalez Mabel Rodriguez
Dorantes Gertrudis Rojas
Perez Ariel Talavera
Frias Ernesto Moreno
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of LV13427B publication Critical patent/LV13427B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LVP-05-152A 2003-04-23 2005-11-22 Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours LV13427B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030092A CU23403A1 (es) 2003-04-23 2003-04-23 Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Publications (1)

Publication Number Publication Date
LV13427B true LV13427B (en) 2006-09-20

Family

ID=40261249

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-05-152A LV13427B (en) 2003-04-23 2005-11-22 Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours

Country Status (32)

Country Link
EP (1) EP1623997B1 (fr)
JP (1) JP2006524194A (fr)
KR (1) KR20060006937A (fr)
CN (2) CN1809592A (fr)
AR (1) AR044076A1 (fr)
AU (1) AU2004232391B2 (fr)
BR (1) BRPI0409664A (fr)
CA (1) CA2523449C (fr)
CL (1) CL2004000843A1 (fr)
CR (1) CR8105A (fr)
CU (1) CU23403A1 (fr)
EA (1) EA008353B1 (fr)
ES (1) ES2535813T3 (fr)
GE (1) GEP20084476B (fr)
HK (1) HK1183492A1 (fr)
HR (1) HRP20050922A2 (fr)
HU (1) HUE025266T2 (fr)
IL (1) IL171541A (fr)
LT (1) LT5353B (fr)
LV (1) LV13427B (fr)
MX (1) MXPA05011368A (fr)
MY (1) MY144620A (fr)
NZ (1) NZ543345A (fr)
PE (1) PE20050422A1 (fr)
PL (1) PL1623997T3 (fr)
RS (2) RS20110319A3 (fr)
SI (1) SI1623997T1 (fr)
TN (1) TNSN05274A1 (fr)
TW (1) TWI343923B (fr)
UY (1) UY28289A1 (fr)
WO (1) WO2004094477A1 (fr)
ZA (1) ZA200509457B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350454T3 (es) 1998-11-27 2011-01-24 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la sustancia ósea.
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EA202092884A1 (ru) 2010-05-14 2022-01-31 Эмджен Инк. Композиции с высокой концентрацией антител
EP2681242B1 (fr) 2011-03-01 2018-01-24 Amgen Inc. Agents liants bispécifiquement sclérostine et dkk-1
EP2688910B1 (fr) 2011-03-25 2019-05-29 Amgen Inc. Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
PL2739311T3 (pl) 2011-08-04 2018-08-31 Amgen Inc. Metoda leczenia szczelinowych uszkodzeń kości
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
EP2869844B2 (fr) 2012-07-05 2023-06-21 UCB Pharma S.A. Traitement de maladies osseuses
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3593812A3 (fr) 2014-03-15 2020-05-27 Novartis AG Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CA3009709A1 (fr) 2015-12-30 2017-07-06 Novartis Ag Therapies a base de cellules effectrices immunitaires dotees d'une efficacite accrue
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3574005B1 (fr) 2017-01-26 2021-12-15 Novartis AG Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique
WO2018144535A1 (fr) 2017-01-31 2018-08-09 Novartis Ag Traitement du cancer à l'aide de protéines chimères du récepteur de lymphocytes t ayant de multiples spécificités
EP3700926A1 (fr) 2017-10-25 2020-09-02 Novartis AG Procédés de conception de cellules d'expression de récepteur antigénique chimérique
EP3700933A1 (fr) 2017-10-25 2020-09-02 Novartis AG Anticorps ciblant cd32b et leurs procédés d'utilisation
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN112166120A (zh) 2018-03-30 2021-01-01 安姆根有限公司 C末端抗体变体
WO2019210153A1 (fr) 2018-04-27 2019-10-31 Novartis Ag Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
WO2019227003A1 (fr) 2018-05-25 2019-11-28 Novartis Ag Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car)
EP3802825A1 (fr) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions et procédés d'immuno-oncologie
KR102344948B1 (ko) * 2018-09-03 2021-12-28 세종대학교산학협력단 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
CN110208409A (zh) * 2019-06-05 2019-09-06 中国海洋大学 一种乳腺癌的生物标志物及其应用
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
WO2024089639A1 (fr) 2022-10-26 2024-05-02 Novartis Ag Formulations lentivirales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2424292T3 (es) * 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
AU717611B2 (en) 1994-10-28 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Tumor-specific antibody fragments, fusion proteins, and uses thereof
WO1997002290A1 (fr) * 1995-06-30 1997-01-23 Mochida Pharmaceutical Co., Ltd. ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
BRPI0409664A (pt) 2006-04-18
AU2004232391B2 (en) 2008-10-30
JP2006524194A (ja) 2006-10-26
RS51853B (en) 2012-02-29
HK1183492A1 (en) 2013-12-27
RS20110319A3 (en) 2012-10-31
CN103012586B (zh) 2014-08-06
IL171541A (en) 2013-11-28
CU23403A1 (es) 2009-08-04
CN103012586A (zh) 2013-04-03
HRP20050922A2 (en) 2007-03-31
NZ543345A (en) 2009-09-25
HUE025266T2 (en) 2016-02-29
PE20050422A1 (es) 2005-06-29
CN1809592A (zh) 2006-07-26
CA2523449A1 (fr) 2004-11-04
ES2535813T3 (es) 2015-05-18
TWI343923B (en) 2011-06-21
UY28289A1 (es) 2004-11-30
RS20050795A (en) 2007-12-31
MXPA05011368A (es) 2006-03-08
TW200504090A (en) 2005-02-01
EP1623997B1 (fr) 2015-04-22
PL1623997T3 (pl) 2015-08-31
LT2005101A (en) 2006-03-27
EA008353B1 (ru) 2007-04-27
MY144620A (en) 2011-10-14
AU2004232391A1 (en) 2004-11-04
CR8105A (es) 2006-05-31
KR20060006937A (ko) 2006-01-20
TNSN05274A1 (en) 2007-07-10
EP1623997A1 (fr) 2006-02-08
CL2004000843A1 (es) 2005-04-15
AR044076A1 (es) 2005-08-24
SI1623997T1 (sl) 2015-07-31
EA200501653A1 (ru) 2006-06-30
RS20110319A2 (en) 2012-02-29
WO2004094477A1 (fr) 2004-11-04
CA2523449C (fr) 2012-09-18
LT5353B (lt) 2006-07-25
ZA200509457B (en) 2006-07-26
GEP20084476B (en) 2008-09-10

Similar Documents

Publication Publication Date Title
EP1623997B1 (fr) Anticorps de recombinaison et fragments reconnaissant le ganglioside n-glycolyl gm3 et leur utilisation dans le diagnostic et le traitement des tumeurs
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP7057843B2 (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
CA2798778C (fr) Anticorps anti-trop-2 humain ayant une activite anticancereuse in vivo
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20100240100A1 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
JP2009537158A (ja) 免疫原性の減少を伴った高親和性ヒトおよびヒト化抗−α５β１インテグリン機能阻害抗体
KR20110067153A (ko) Ｍｕｃ１＊ 항체
US10035848B2 (en) Antibody targeting cell surface deposited complement protein C3d and use thereof
ES2296952T3 (es) Metodo para tratar el mieloma multiple.
CN110382532A (zh) 抗g-csf抗体及其用途
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
JP2022539344A (ja) 抗ｃｅａ抗体及びその応用
AU2013325443A1 (en) Anti-hDlk-1 antibody having an anti-tumor activity in vivo
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
WO2013147076A1 (fr) SUPPRESSION DE FIBROSE PAR L'INHIBITION DE LA FONCTION DE L'INTÉGRINE α8β1
CN114729057A (zh) 抗岩藻糖基-gm1抗体
CN113597432A (zh) 抗EpCAM抗体及其应用
CN110563847A (zh) 用于治疗性用途的免疫检查点抑制剂
US20220185911A1 (en) Therapeutic antibodies for treating lung cancer
CN117412992A (zh) 靶向cd47和pd-l1的双特异性抗体及其使用方法
MX2008000884A (en) Anti-cd26 antibodies and methods of use thereof